Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance

Summary

Experimental results are strongly suggesting that PCSK9 and FXR could occur in the physiopathology of human joined dyslipidemia. But no data in the literature can validate the potential role of these two genes in the lipidic and glucidic metabolism control in physiopathological situations. This protocol is based on the hypothesis that the expression levels of PCSK 9 and FXR are modified for some patients suffering from insulin resistance and dyslipidemia.

Conditions

• Obesity

Interventions

PROCEDURE

biopsy of muscle, of liver, and of adipose tissue

biopsy of muscle, of liver, and of adipose tissue

PROCEDURE

clamp euglycemic - hyperglycemic

clamp euglycemic-hyperglycemic

BEHAVIORAL

diet

diet

OTHER

biopsies for biological and genetic analyses

biopsies for biological and genetic analyses

Sponsors & Collaborators

• Nantes University Hospital

  lead OTHER

Principal Investigators

• Bertrand Cariou, MD · Nantes University Hospital

• Michel Krempf, MD · Nantes University Hospital

• Yassine Zaïr, MD · Nantes University Hospital

• Eric Letessier, MD · Nantes University Hospital

• Charles Couet, MD · CHU de Tours

• Noël Huten, MD · CHU de Tours

• Philippe Topart, MD · CHU de Brest

• David Lechaux, MD · CHU de St Brieuc

• Jean-Pierre Faure, MD · Poitiers University Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-02-29

Primary Completion

2013-11-30

Completion

2013-11-30

Countries

• France

Study Locations